STP-251G

N/A

Report date: 2023/08/07 17:46:52

NME

Base Information

Drug NameSTP-251G

Drug Alias NameSTP-251G

ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Small molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionApolipoprotein C-III inhibitorsTransmembrane protease serine 6 inhibitors

TargetsApolipoprotein C-IIITransmembrane protease serine 6

Therapy Area/IndicationsHypercholesterolemiaHemochromatosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSirnaomics

China Registration ClassN/A

Develop Information

Active CompaniesSirnaomics

Inactive CompaniesN/A

Active IndicationsHypercholesterolemiaHemochromatosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A